Application of hybridAPC in the Treatment of Barrett

Last updated: January 25, 2018
Sponsor: Changhai Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heartburn

Esophageal Disorders

Barrett's Esophagus

Treatment

N/A

Clinical Study ID

NCT03418584
XHD2017
  • Ages 18-70
  • All Genders

Study Summary

The purpose of this study is to evaluate the efficacy and safety of the new technique of HybridAPC in the treatment of Barrett.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients age is from 18 to 70.

  2. Patients who were diagnosed with Barrett's esophagus.

  3. Informed consent.

Exclusion

Exclusion Criteria:

  1. Patient with severe cardiopulmonary dysfunction is unable to tolerated by endoscopy.

  2. Severe bleeding tendency.

  3. Poor compliance.

  4. Patient is very ill and life expectancy is less than 2 years.

  5. Esophageal varices or venous aneurysms, and no effective prevention or treatment forbleeding.

  6. Severe esophageal stenosis.

  7. Pregnancy.

  8. Lesion is located in esophageal diverticulum or spread their diverticulum.

Study Design

Total Participants: 80
Study Start date:
December 05, 2017
Estimated Completion Date:
December 05, 2021

Study Description

After thermal ablation of Barrett's esophagus, stricture formation is reported in 5 to over 10% of patients. Submucosal fluid injection prior to ablation may lower the risk of stricture formation. The new technique of HybridAPC which combines submucosal injection with APC is considered to reduce the complication.

Connect with a study center

  • Department of Gastroenterology, Changhai Hospital, Second Military Medical University

    Shanghai, Shanghai 200433
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.